Molecular Templates, Inc. (MTEM)
Molecular Templates, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $0.00, down 0.00% on the session, giving a market capitalisation of $658. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -14.2%. Its beta of 1.53 implies it has historically moved more than the broad market.
Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical firm dedicated to the identification and progression of biological therapies for oncology and other significant health conditions. The company's core development strategy relies on its unique engineered toxin body (ETB) drug platform to construct a robust pipeline of treatments. Currently, several of its ETB candidates are undergoing Phase I clinical evaluation: MT-5111 is being assessed for HER2-positive cancers; MT-0169 is in trials for individuals with relapsed or refractory myeloma; and MT-6402 targets patients who have not responded to prior PD-1/PD-L1 antibody treatments. Beyond these, Molecular Templates is also developing ETBs to engage other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. Furthermore, the company has forged a collaborative partnership with Bristol Myers Squibb to jointly discover and advance innovative ETB-based products designed for a diverse array of biological targets. Established in 2001, Molecular Templates, Inc. is headquartered in Austin, Texas.
Molecular Templates, Inc. is most often compared with the following Healthcare names: